Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: Focus on panitumumab

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1221-1227

  Hoda, Daanish ^a   Simon, George R ^a   Garrett, Christopher R ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; Monoclonal antibody; Panitumumab

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; STEROID;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; GENE MUTATION; HAIR DISEASE; HUMAN; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUTATIONAL ANALYSIS; NAUSEA; OPTIMAL DRUG DOSE; PARONYCHIA; REVIEW; SKIN DISEASE; SKIN EXFOLIATION; SKIN TOXICITY;

EID: 61549138171     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Amado RG, Wolf M, Peeters M, et al. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with colorectal cancer. J Clin Oncol, 26:1626-34.
2. Barault L, Veyrie N, Jooste V, et al. 2008. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer, 122:2255-9.
3. Bokemeyer C, Bondarenko I, Hartmann JT, et al. 2008. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience. Proc Am Soc Clin Oncol, 26 (abstract 4000).
4. Chung KY, Shia J, Kemeny N, et al. 2005. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by inummohistochemistry. J Clin Oncol, 23:1803-10.
5. Cocker KJ, Staros JV, Guyer CA, et al. 1994. A kinase-negative epidermal growth factorreceptor that retains the capcity to stimulate DNA synthesis. Proc Natl Acad Sci U S A, 91:6967-71.
6. Cunningham D, Humblett Y, Siena S, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med, 351:337-45.
7. [EMEA] European Medicines Evaluation Agency European Public Assesment Report October. 2007. [online]. URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/vectibix/H-741-en1.pdf
8. Ewald JA, Wilkinson JC, Guyer CA, et al. 2003. Ligand-and kinase activity independentcell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp Cell Res, 282:121-31.
9. FDA. 2006. FDA approves Vectibix (panitumumab) to treat metastatic colorectal carcinoma [online]. URL: http://www.fda.gov/cder/Offices/OODP/ whatsnew/Panitumumab.htm.
10. Fox LP. 2006. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park), 20:26-34.
11. Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances. 1997. World Health Organization [online]. pp. 27-28. URL: http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf
12. Hecht JR, Patnaik A, Berlin J, et al. 2007. Panitumumab montherapy in patients with previously treated metastatic colorectal cancer. Cancer, 110:980-7.
13. Hecht J, Posey J, Tchekmedyian E, et al. 2006. Panitumumab in combination with 5-fluorouracil, leucovorin, and Irinotecan or FOLFIRI for the first-line treatment of metastatic colorectal cancer. Gastrointestinal Cancer Symposium (abstract 237).
14. Hecht J, Chidiac T, Mitchell E, et al. 2007. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab in metastatic colorectal cancer. Ninth World Congress on Gastrointestinal Cancer (abstract 9).
15. Hecht JR, Mitchell E, Chidiac T, et al. 2008. Interim results from PACCE: irinotecan/bevacizumab ± panitumumab as first-line treatment for metastatic colorectal cancer. Gastrointestinal Cancer Symposium (abstract 279).
16. Kawamoto TK, Sato JD, Le A, et al. 1983 Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A, 80:1337-41.
17. Keiholz U, Arnold D, Niederle N, et al. 2005. Erlotinib as second and third line montherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. Proc Am Soc Clin Oncol, 23(abstract 3575).
18. Lievre A, Bachet JB, Le Corre D, et al. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66:3992-5
19. Lockhart AC, Berlin JD. 2005. The epidermal growth factor as a receptor target for colorectal cancer therapy. Semin Oncol, 32:52-60.
20. Mendelsohn J. 2002, Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol, 20:1-13s.
21. Mitchell EP, Perez-Soler R, Van Cutsem E, et al. 2007. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park), 21:4-9.
22. Mitchell EP, LaCouture M, Shearer H, et al. 2008. A phase II, open-label, randomized clinical trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer patients receiving second-line FOLFIRI or irinotecan-only chemotherapy with panitumumab: early analysis. Proceedings ASCO Gastrointestinal Cancer Symposium (abstract 462).
23. Moroni M, Veronese S, Benvenuti S, et al. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol, 6:257-8.
24. Overholser JP, Prewett MC, Hooper AT, et al. 2000 Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer, 89:74-82.
25. Prewett M, Hooper A, Bassi R, et al. 2002. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res, 8:994-1003.
26. Prewett M, Deevi DS, Bassi R, et al. 2007. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res, 13:7432-40.
27. Rothenberg ML, LaFleur B, Levy DE, et al. 2005. Randomized phase II trial of the clinical and biological effects of two doses levels of gefitinib in patients with recurrent colorectal cancer. J Clin Oncol, 23:9265-74.
28. Sako Y, Minoghchi S, Yanagida T, 2000. Single-molecule imaging of EGFR signaling on the surface of living cells. Nat Cell Biol, 2:168-172.
29. Saltz L, Keis M, Abbruzzese JL, et al. 2003. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol, 22(abstract 817).
30. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. 2004. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol, 22:1201-8.
31. Siena S, Tabernero J, Buttes RL, et al. 2008. Phase III study (PRIME/ 20050203) of panitumumab with FOLFOX compared with FOLFOX alone in patients with previously untreated metastatic colorectal cancer: pooled safety data. Proc Am Soc Clin Oncol, 25(abstract 4034).
32. Sartore-Bianchi A, Moroni M, Veronese S, et al. 2007. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol, 25:3238-45.
33. Sato JD, Kawamoto, Le AD, et al. 1983. Biologic effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med, 1:511-29.
34. Tejpar S, Peeters M, Humblet Y et al. 2007. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic, pharmacodynamic and efficacy data. Proc Am Soc Clin Oncol, 25(abstract 4037).
35. Tsuchihashi Z, Khambata-Ford S, Hanna N, et al. 2005. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med, 353:208-9.
36. Van Cutsem E, Peeters M, Siena S, et al. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 25:1658-64.
37. Van Cutsem E, Lang I, D'haens G, et al. 2008. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol, 26(abstract 2).
38. Weihua Z, Tsan R, Huang WC, et al. 2008. Survival of cancer cells is maintained by \EGFR independent of its kinase activity. Cancer Cell, 13:385-93.
39. Weiner LM, Belldegrun AS, Crawford J, et al. 2008. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res, 14:502-8.
40. Yang XD, Jia XC, Corvalan JR, et al. 2001. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol, 38:17-23.